232 related articles for article (PubMed ID: 29866745)
1. The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown
Wahba A; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2018 Aug; 17(8):1717-1726. PubMed ID: 29866745
[TBL] [Abstract][Full Text] [Related]
2. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
3. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown
Timme CR; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2018 Jun; 17(6):1207-1216. PubMed ID: 29549168
[TBL] [Abstract][Full Text] [Related]
4. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
5. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
6. Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
[TBL] [Abstract][Full Text] [Related]
7. Coculture with astrocytes reduces the radiosensitivity of glioblastoma stem-like cells and identifies additional targets for radiosensitization.
Rath BH; Wahba A; Camphausen K; Tofilon PJ
Cancer Med; 2015 Nov; 4(11):1705-16. PubMed ID: 26518290
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
9. The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
Yun HS; Lee J; Kil WJ; Kramp TR; Tofilon PJ; Camphausen K
Mol Cancer Ther; 2021 Sep; 20(9):1672-1679. PubMed ID: 34158343
[TBL] [Abstract][Full Text] [Related]
10. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity.
Lehman SL; Wechsler T; Schwartz K; Brown LE; Porco JA; Devine WG; Pelletier J; Shankavaram UT; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2022 Sep; 21(9):1406-1414. PubMed ID: 35732578
[TBL] [Abstract][Full Text] [Related]
12. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
Kashyap T; Murray J; Walker CJ; Chang H; Tamir S; Hou B; Shacham S; Kauffman MG; Tripp RA; Landesman Y
Antiviral Res; 2021 Aug; 192():105115. PubMed ID: 34157321
[TBL] [Abstract][Full Text] [Related]
13. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA; Devine S; Shacham S; Kauffman M; Marcucci G; Blum W; Garzon R
Blood; 2015 Apr; 125(17):2689-92. PubMed ID: 25716206
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
16. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
[TBL] [Abstract][Full Text] [Related]
17. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
18. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
[TBL] [Abstract][Full Text] [Related]
20. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]